cas 6228-73-5|| where to buy Cyclopropanecarboxamide

Nom du produit:Cyclopropanecarboxamide

IUPAC Name:cyclopropanecarboxamide

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM202436-1000g	in stock	Ǥůů

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 6228-73-5 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:6228-73-5; Formule moléculaire:C4H7NO; Point de fusion:-; Code SMILES:O=C(C1CC1)N; Densité:

: Numéro de catalogue:CM202436; Poids moléculaire:85.11; Point d'ébullition:248.5°C at 760 mmHg; N° Mdl:MFCD00013729; Stockage:Store at room temperature.

: Cyclopropanes; Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.

: Deucravacitinib; BMY announced new four-year Sotyktu (deucravacitinib) data demonstrating durable response rates and consistent safety in moderate-to-severe plaque psoriasis. Deucravacitinib is a specific, oral, intracellular TYK2 inhibitor that targets immune responses driven by type 1 IFN and IL-23 that contribute to psoriasis pathogenesis, including IL-17 production and Th1/Th17 polarization.